Results 31 to 40 of about 1,210,671 (242)
Serum immune mediators as novel predictors of response to anti-PD-1/PD-L1 therapy in non-small cell lung cancer patients with high tissue-PD-L1 expression [PDF]
, 2023 Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related morbidity and mortality worldwide. Immune checkpoint inhibitors (ICIs) including anti-PD-1 and anti-PD-L1 antibodies, have significantly changed the treatment outcomes with better ...
Raza, Afsheen +45 more
core +1 more source
Soluble PD-L1 works as a decoy in lung cancer immunotherapy via alternative polyadenylation
JCI Insight, 2022 Immune checkpoint therapy targeting the PD-1/PD-L1 axis is a potentially novel development in anticancer therapy and has been applied to clinical medicine.
Ray Sagawa +18 more
doaj +1 more source
Cell Communication and Signaling, 2023 Background PD-L1, a transmembrane ligand for immune checkpoint receptor PD1, has been successfully targeted to activate an anti-tumor immune response in a variety of solid tumors, including non-small cell lung cancer (NSCLC).
Anudari Letian +5 more
doaj +1 more source
The function and regulation of PD-L1 in immunotherapy
ADMET and DMPK, 2017 PD-L1, also known as B7-H1, is a type I transmembrane protein, which is expressed in different kinds of tumor cells. It is correlated with poor clinical outcome of patients with various types of tumors.
Libin Guo, Yao Lin, Hang Fai Kwok
doaj +1 more source
PD‐L1 methylation regulates PD‐L1 expression and is associated with melanoma survival [PDF]
Pigment Cell & Melanoma Research, 2018 AbstractThe aim of this study is to determine the significance of programmed death ligand 1 (PD‐L1 or CD274) methylation in relation to PD‐L1 expression and survival in melanoma. Despite the clinical importance of therapies targeting the PD‐1/PD‐L1 immune checkpoint in melanoma, factors regulating PD‐L1 expression, including epigenetic mechanisms, are ...
Goran Micevic +3 more
openaire +2 more sources
CD274/PD-L1 gene amplification and PD-L1 protein expression are common events in squamous cell carcinoma of the oral cavity. [PDF]
, 2016 Immunomodulatory therapies, targeting the immune checkpoint receptor-ligand complex PD-1/PD-L1 have shown promising results in early phase clinical trials in solid malignancies, including carcinomas of the head and neck.
Pfarr, Nicole +19 more
core +2 more sources
STING mediates nuclear PD-L1 targeting-induced senescence in cancer cells
Cell Death and Disease, 2022 Immune checkpoint molecule programmed death-ligand 1 (PD-L1) is overexpressed in cancer cells and imparts resistance to cancer therapy. Although membrane PD-L1 has been targeted for cancer immune therapy, nuclear PD-L1 was reported to confer cancer ...
Je-Jung Lee +5 more
doaj +1 more source
Role of regulation of PD-1 and PD-L1 expression in sepsis
Frontiers in Immunology, 2023 Long term immunosuppression is problematic during sepsis. The PD-1 and PD-L1 immune checkpoint proteins have potent immunosuppressive functions. Recent studies have revealed several features of PD-1 and PD-L1 and their roles in sepsis. Here, we summarize
Teng Zhang, Li Yu-Jing, Tao Ma
doaj +1 more source
, 2019 Figure S1. Anti-PD-L1 antibody exhibited in vivo activity on GV369-CON B-cell lymphoma. A and B: CD8+T cell percentage was enhanced, as well as CD8+T cell apoptosis and Fas expression were inhibited in GV369-CON group treated with anti-PD-L1 antibody.
Hui-Juan Zhong (799289) +9 more
core +1 more source
, 2023 It has been reported that mismatch repair deficient (d-MMR) tumors show sensitivity to immune checkpoint inhibitors. We aimed to evaluate the correlation of d-MMR and PD-1/PD-L1 expression in invasive urothelial carcinoma of the bladder.
Kıran, Merve M. +3 more
core +1 more source